The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges

被引：39

作者：

Rogers, Jane E. ^{[1
]}

Dasari, Arvind ^{[2
]}

Eng, Cathy ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Pharm Clin Programs, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA

来源：

ONCOLOGIST | 2016年 / 21卷 / 05期

关键词：

Pregnancy; Antineoplastics; Colorectal neoplasms; Monoclonal antibodies; COLON-CANCER; MONOCLONAL-ANTIBODIES; DESCENDING COLON; RECTAL-CANCER; IN-UTERO; IRINOTECAN; PHARMACOKINETICS; ERLOTINIB; AGENTS; IMPACT;

D O I：

10.1634/theoncologist.2015-0362

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer diagnosed during pregnancy has increased because of delayed child-bearing and the known occurrence of age-dependent malignancies. Cases of colorectal cancer (CRC) in pregnancy have recently been reported. With the expected rise in CRC diagnosed in young adults coupled with the current trend of delayed child-bearing, CRC during pregnancy is likely to increase. Treating pregnant women with CRC by using antineoplastics presents a dilemma because there are many unknowns to guide treatment decisions. We review the issues regarding the use of 10 CRC-approved agents in pregnancy.

引用

页码：563 / 570

页数：8